[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Definium Therapeutics Inc (DFTX)

Definium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,338,857
  • Shares Outstanding, K 99,698
  • Annual Sales, $ 0 K
  • Annual Income, $ -183,790 K
  • EBIT $ -193 M
  • EBITDA $ -195 M
  • 60-Month Beta 2.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.91

Options Overview Details

View History
  • Implied Volatility 118.22% (+4.76%)
  • Historical Volatility 133.14%
  • IV Percentile 85%
  • IV Rank 55.71%
  • IV High 162.76% on 06/03/26
  • IV Low 62.19% on 04/15/26
  • Expected Move (DTE 19) 4.00 (9.18%)
  • Put/Call Vol Ratio 0.68
  • Today's Volume 884
  • Volume Avg (30-Day) 2,872
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 68,798
  • Open Int (30-Day) 74,610
  • Expected Range 39.53 to 47.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.55
  • Number of Estimates 5
  • High Estimate $-0.51
  • Low Estimate $-0.58
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.29 +8.02%
on 07/28/26
48.50 -10.27%
on 07/16/26
-3.52 (-7.48%)
since 06/30/26
3-Month
19.33 +125.14%
on 05/19/26
49.20 -11.54%
on 06/30/26
+21.64 (+98.90%)
since 04/30/26
52-Week
7.96 +446.73%
on 08/01/25
49.20 -11.54%
on 06/30/26
+34.49 (+381.95%)
since 07/30/25

Most Recent Stories

More News
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 43.52 (-2.18%)
Definium Therapeutics: Four Straight Misses Before the Pattern Either Breaks or Calcifies

Barchart Research What to Expect from DFTX Earnings DFTX Generated July 29, 2026 Current Price $42.13 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 4.78% Definium Therapeutics: Four Straight...

DFTX : 43.52 (-2.18%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 43.52 (-2.18%)
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms 1,2,3 Patients experience high rates...

DFTX : 43.52 (-2.18%)
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

Data highlight the challenges of achieving response and sustained remission in newly diagnosed and established GAD patients with existing therapies

DFTX : 43.52 (-2.18%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 43.52 (-2.18%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 7.82 (-3.93%)
CMPS : 11.35 (-1.90%)
GHRS : 28.07 (-1.09%)
JNJ : 256.35 (+0.21%)
DFTX : 43.52 (-2.18%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 7.82 (-3.93%)
CMPS : 11.35 (-1.90%)
GHRS : 28.07 (-1.09%)
JNJ : 256.35 (+0.21%)
DFTX : 43.52 (-2.18%)
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address...

DFTX : 43.52 (-2.18%)
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address...

DFTX : 43.52 (-2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK....

See More

Key Turning Points

3rd Resistance Point 46.89
2nd Resistance Point 45.95
1st Resistance Point 44.73
Last Price 43.52
1st Support Level 42.57
2nd Support Level 41.63
3rd Support Level 40.41

See More

52-Week High 49.20
Last Price 43.52
Fibonacci 61.8% 33.45
Fibonacci 50% 28.58
Fibonacci 38.2% 23.71
52-Week Low 7.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.